Pharming Group (PHAR) Stock Statistics & Valuation Metrics

Pharming Group has a market cap or net worth of $1.16B. The enterprise value is $957.53M.

Pharming Group has 68,514,760 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pharming Group’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -3.61%.

The current PE Ratio of Pharming Group is 1223.6. Pharming Group’s PEG ratio is -3.28.

In the last 12 months, Pharming Group had revenue of 297.20M and earned -11.84M in profits. Earnings per share was -0.17.

In the last 12 months, operating cash flow was 51.32M and capital expenditures -620.69K, giving a free cash flow of 50.70M billion.

Pharming Group pays an annual dividend of ―, resulting in a dividend yield of ―

Pharming Group upcoming earnings date is Mar 12, 2026, Before Open (Confirmed).

Pharming Group as a current ratio of 3.77, with Debt / Equity ratio of 49.47%

In the past 12 months, Pharming Group has paid 3.35M in taxes.

Pharming Group EV to EBITDA ratio is 44.60, with an EV/FCF ratio of -280.81.

Pharming Group has $141.54M in cash and marketable securities with $111.52M in debt, giving a net cash position of $30.02M billion.

Gross margin is 89.90%, with operating margin of -2.90%, and net profit margin of -3.98%.

The average price target for Pharming Group is $39.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy